Meetings

ETFAD 2025 Annual meeting program

Wednesday | September 17 | 8:30 AM- 10.00 AM.

Also see: EADV Congress 2025 – Paris, France – Session Detail

Room: Paris Sud

  • Atopic dermatitis and eczema of the elderly are distinct entities: Different patterns of patient history, clinical presentation, and diagnostic findings. Susanne Radonjic-Hoesli 
  • Chronic hand eczema is a type 2 disease: evidence from integrated clinical trial and molecular profiling. Marie Tauber
  • Abrocitinib Treatment Restores Epidermal Integrity and Barrier Function in Atopic Dermatitis. Jan Hartmann
  • Turnover of basement-membrane and epidermal associated collagens is increased in Atopic Dermatitis patients with inadequate response to Dupilumab. Magnus Kær Nørgaard Have
  • Effectiveness and safety of dupilumab versus tralokinumab in atopic dermatitis: a propensity score– matched analysis from the BioDay registry. Lian van der Gang
  • Patients with and without head-neck dermatitis treated with dupilumab in the TREATgermany population. Annice Heratizdeh
  • Successful dose reduction of Janus-kinase inhibitors in well-controlled atopic dermatitis: a prospective, multicenter, real-world study. Anne Schlösser
  • Association between novel systemic immunomodulatory medications and achievement of super-response in patients with moderate-to-severe atopic eczema: results from the UK-Irish Atopic eczema Systemic TherApy Register (A-STAR). Carsten Flohr
  • A DElphi survey on narrowband ultraviolet B phototherapy for ATopic Eczema (DEBATE): consensus on clinical practices. Eva Knöps
  • Analysis of the Survey on the Role of Artificial Intelligence in the Management of Atopic Dermatitis. Jean Francois Stalder.